survival outcomes
Showing 1 - 8 of 8
Cervical Carcinoma, Chemoradiotherapy, Anti-programmed Cell Death Receptor 1 Trial in Beijing (Camrelizumab plus Concurrent
Recruiting
- Cervical Carcinoma
- +8 more
- Camrelizumab plus Concurrent chemoradiotherapy
-
Beijing, Beijing, ChinaLei Li
Apr 5, 2022
Ovarian Carcinoma, Survival Outcomes, Adverse Events Trial in Beijing (Niraparib plus anlotinib)
Recruiting
- Ovarian Carcinoma
- +8 more
- Niraparib plus anlotinib
-
Beijing, Beijing, ChinaLei Li
Apr 5, 2022
Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus
Recruiting
- Recurrent Cervical Carcinoma
- +9 more
- Tislelizumab plus radiotherapy
-
Beijing, Beijing, ChinaLei Li
Apr 1, 2022
Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Recurrent Ovarian Carcinoma Trial in Beijing (Albumin-bound paclitaxel and
Recruiting
- Ovarian Carcinoma
- +6 more
- Albumin-bound paclitaxel and bevacizumab
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Prognosis of Low-grade Endometrial Stromal Sarcoma
Recruiting
- Low Grade Endometrial Stromal Sarcoma of Uterus (Diagnosis)
- +6 more
- Surgical treatment with and without fertility-sparing procedures
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Chromosomal Instability in Ovarian Cancer
Recruiting
- Epithelial Ovarian Cancer
- +7 more
- Testing for chromosomal instability (CIN)
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Targeted Therapy, Chemo, Recurrent Cervical Carcinoma Trial in Beijing (Donafenib combined with paclitaxel and platinum ± PD-1
Recruiting
- Targeted Therapy
- +6 more
- Donafenib combined with paclitaxel and platinum ± PD-1 antibody
-
Beijing, Beijing, ChinaLei Li
Mar 26, 2022
Breast Cancer, Elderly Patient, Wide Local Excision Trial in Beijing
Not yet recruiting
- Breast Cancer
- +4 more
-
Beijing, Beijing, ChinaDepartment of Breast Surgery,Peking Union Medical College Hospit
Jun 8, 2020